Previsioni di mercato dei radiofarmaci per l’Asia Pacifico fino al 2028 – Impatto del COVID-19 e analisi regionale per tipologia (medicina nucleare diagnostica e medicina nucleare terapeutica), applicazione (oncologia, cardiologia, neurologia e altre) e utente finale (ospedali, centri di imaging, centri accademici e Centri di ricerca e altri)

Introduzione al mercato

L\'APAC è composta da cinque paesi principali: Cina, Giappone, India, Australia e Corea del Sud. Il mercato viene valutato anche per il resto dei paesi dell\'Asia Pacifico. Il Giappone ha guidato il mercato durante il periodo di previsione. Negli ultimi anni, il Giappone ha aumentato la sua attenzione verso il campo della medicina nucleare. Il Giappone è entrato nell’era della popolazione geriatrica in più rapida crescita; il crescente invecchiamento della popolazione ha portato alla trasformazione dei sistemi sanitari. Ad esempio, secondo il World Economic Forum, attualmente in Giappone ci sono 2,3 miliardi di persone sulla settantina. Nel Paese si osserva una transizione sanitaria avanzata che esercita sempre più pressione sulla sostenibilità dei suoi sistemi sanitari. L’aumento della popolazione geriatrica è responsabile dell’aumento del carico di malattie nella regione. Le organizzazioni governative e gli istituti di ricerca sono coinvolti nella produzione di radiofarmaci. Ad esempio, il Dipartimento di sviluppo dei radiofarmaci, una parte dell’Istituto nazionale di scienze radiologiche, mira a sviluppare radiofarmaci utili per la diagnosi e il trattamento clinici, sviluppando nuovi radionuclidi necessari per la sintesi di farmaci e la produzione di tecniche di etichettatura. La crescita vertiginosa nei paesi emergenti e il crescente utilizzo di farmaci nucleari per trattamenti personalizzati sono i fattori principali che guidano la crescita del mercato dei radiofarmaci nell\'area APAC.

In caso di COVID-19, l\'area APAC è fortemente colpita, in particolare l\'India. Le pratiche mediche nella regione continuano ad adattarsi alle sfide del COVID-19. Da un lato, gli operatori sanitari stanno rispondendo alla pandemia e, dall’altro, garantiscono interruzioni minime alle procedure e ai ricoveri non correlati al COVID. Ospedali e altre strutture sanitarie in tutto il mondo sono costretti a rinviare le procedure elettive, come gli interventi chirurgici. La maggior parte delle terapie non urgenti sono state rinviate. La pandemia di COVID-19 ha colpito i servizi sanitari sotto molteplici aspetti, a partire dall’interruzione del regolare flusso di pazienti verso le strutture sanitarie, stressando e sovraccaricando le risorse sanitarie, fino a portare all’implementazione di misure protettive aggiuntive e al distanziamento sociale con un maggiore utilizzo delle risorse sanitarie. telemedicina e medicina virtuale. Come approccio precauzionale, gli ambulatori oncologici hanno implementato misure specifiche per ridurre il numero di pazienti negli ambulatori, ridurre le procedure non necessarie o elettive e dimettere i pazienti dai servizi di degenza. Ciò ha avuto un impatto negativo sulla crescita del mercato dei radiofarmaci nella regione. Inoltre, anche gli operatori del mercato sono stati colpiti dalla pandemia a causa degli ostacoli della catena di approvvigionamento e della riduzione della domanda. Il segmento farmaceutico specializzato, in particolare quello radiofarmaceutico, è stato influenzato dal COVID-19 e dalla concorrenza nel settore radiofarmaceutico. Anche prima della pandemia, la catena di fornitura della medicina nucleare era molto complessa, a seconda della disponibilità di materie prime, delle operazioni degli impianti di produzione e dell\'affidabilità del trasporto aereo. Pertanto, i fattori sopra menzionati stanno incidendo negativamente sul mercato dei radiofarmaci nella regione.

Panoramica e dinamiche del mercato

Si prevede che il mercato dei radiofarmaci nell\'area APAC crescerà da 1.384,59 milioni di dollari nel 2021 a 2.661,38 milioni di dollari entro il 2028; si stima che crescerà a un CAGR del 9,8% dal 2021 al 2028. La terapia alfa mirata (TAT) è la tecnica più recente e in evoluzione utilizzata per il trattamento del cancro locale e sistemico. La ricerca preclinica e gli studi clinici dimostrano che i radionuclidi che emettono alfa uccidono le cellule tumorali mirate e non danneggiano le cellule sane (citotossicità selettiva). 211At, 213Bi, 225Ac e 227Th sono tra i radioisotopi che emettono alfa utilizzati per etichettare vettori di targeting come gli anticorpi monoclonali; gli anticorpi monoclonali marcati con radionuclidi emittenti α stanno emergendo come una radioimmunoterapia efficace. I radioisotopi a corto raggio (particelle α) vengono utilizzati per il trattamento di pazienti con cancro ematologico. Le radiazioni alfa sono adatte per uccidere le cellule tumorali isolate nei sistemi vascolare e linfatico, nonché per la regressione dei tumori disturbando le reti capillari tumorali per colpire e uccidere le cellule endoteliali capillari tumorali (EC). La terapia con radioisotopo alfa-emettitore di radio-223 è l’unico concetto approvato per il trattamento del cancro con radioisotopi interni che emettono alfa. Il decadimento degli elementi radioattivi dopo aver raggiunto il tessuto maligno rilascia radiazioni che distruggono il tumore senza causare danni significativi ai tessuti sani adiacenti. Le radiazioni alfa sono molto localizzate e penetrano al massimo in 2-10 strati cellulari. Le cellule sane dei tessuti circostanti possono in una certa misura riprendersi da sole dai danni causati dalle radiazioni. L\'imaging nucleare utilizza emettitori gamma che hanno una lunga durata, che consente l\'eliminazione del sangue poiché il tumore aumenta l\'assorbimento del coniugato nel tempo, migliorando così il contrasto. Gli agenti di imaging nucleare consentono la diagnosi di tumori e organi. Inoltre, la crescente consapevolezza sulla radioimmunoterapia alfa e l’aumento della disponibilità di terapie per le procedure di trattamento del cancro stanno stimolando la domanda di imaging nucleare. Pertanto, l\'uso preferito della radioimmunoterapia alfa nel trattamento del cancro sta alimentando la crescita del mercato dei radiofarmaci nell\'area APAC.

Segmenti chiave del mercato

In termini di tipologia, il segmento della medicina nucleare diagnostica ha rappresentato la quota maggiore del mercato dei radiofarmaci dell\'APAC nel 2020. In termini di applicazione, il segmento oncologico ha detenuto una quota di mercato maggiore del mercato dei radiofarmaci dell\'APAC in 2020. Inoltre, nel 2020 il segmento ospedaliero ha detenuto una quota maggiore del mercato dei radiofarmaci nell\'area APAC in base all\'utente finale.

Principali fonti e aziende elencate

Alcune delle principali fonti primarie e secondarie a cui si fa riferimento per la preparazione di questo rapporto sul mercato dei radiofarmaci nell\'area APAC sono siti Web aziendali, relazioni annuali, relazioni finanziarie, documenti governativi nazionali e database statistici, tra gli altri. Le principali aziende elencate nel rapporto sono Advanced Accelerator Applications; Bayer AG; Bracco Imaging SpA; Cardinale Salute Inc; Curio; ECZACIBAČI MONROL NUCLEAR PRODUCTS CO.; ELETTRICO GENERALE; Lantheus Medical Imaging, Inc.; Nordione; e RADIOISOTOPI NTP.

Rapporto sui motivi per acquistare

Comprendere il panorama del mercato dei radiofarmaci dell\'APAC e identificare i segmenti di mercato che hanno maggiori probabilità di garantire un forte ritorno
Mantenere un vantaggio comprendendo il panorama competitivo in continua evoluzione per il mercato dei radiofarmaci dell\'APAC
Pianificare in modo efficiente operazioni di fusione e acquisizione e accordi di partnership nel mercato dei radiofarmaci dell\'area APAC identificando i segmenti di mercato con le vendite probabili più promettenti
Aiuta a prendere decisioni aziendali consapevoli grazie a un\'analisi perspicace e completa delle prestazioni di mercato dei vari segmenti dal mercato dei radiofarmaci APAC
Ottenere previsioni sui ricavi di mercato per vari segmenti dal 2021 al 2028 nella regione APAC.

Segmentazione del mercato dei radiofarmaci APAC

Mercato dei radiofarmaci APAC - Per tipo

Medicina nucleare diagnostica
- SPECT
- PET
Medicina nucleare terapeutica
- Emettitori alfa
- Emettitori beta
- Isotopi della brachiterapia

< p>Mercato dei radiofarmaci nella regione APAC - per applicazione

Oncologia
Cardiologia
Neurologia
Altro

Mercato dei radiofarmaci APAC - Per utente finale

Ospedali
Centri di imaging
Centri accademici e di ricerca ;
Altri

Mercato dei radiofarmaci nell\'area APAC: per paese

Mercato dei radiofarmaci nell\'area APAC - Profili aziendali

TABLE OF CONTENTS

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 APAC Radiopharmaceuticals Market – By Type

1.3.2 APAC Radiopharmaceuticals Market – By Application

1.3.3 APAC Radiopharmaceuticals Market – By End User

1.3.4 APAC Radiopharmaceuticals Market– By Country

2. Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. APAC Radiopharmaceuticals Market– Market Landscape

4.1 Overview

4.2 APAC PEST Analysis

4.3 Experts Opinion

5. APAC Radiopharmaceuticals Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Surging Use of Alpha Radio Immunotherapy for Cancer Treatment

5.1.2 Escalating Advancements in Nuclear Imaging Techniques

5.2 Market Restraints

5.2.1 Presence of Alternatives

5.3 Market Opportunities

5.3.1 Soaring Growth in Emerging Countries

5.4 Future Trends

5.4.1 Rising Use of Nuclear Medicines for Personalized Treatment

5.5 Impact Analysis

6. Radiopharmaceuticals Market– APAC Analysis

6.1 APAC Radiopharmaceuticals Market Revenue Forecast and Analysis

7. APAC Radiopharmaceuticals Market Analysis – By Type

7.1 Overview

7.2 APAC Radiopharmaceuticals Market Revenue Share, by Type (2021 and 2028)

7.3 Diagnostic Nuclear Medicine

7.3.1 Overview

7.3.2 Diagnostic Nuclear Medicine: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.3.3 SPECT

7.3.3.1 Overview

7.3.3.2 SPECT: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.3.4 PET

7.3.4.1 Overview

7.3.4.2 PET: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.4 Therapeutic Nuclear Medicine

7.4.1 Overview

7.4.2 Therapeutic Nuclear Medicine: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.4.3 Alpha Emitters

7.4.3.1 Overview

7.4.3.2 Alpha Emitters: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.4.4 Beta Emitters

7.4.4.1 Overview

7.4.4.2 Beta Emitters: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.4.5 Brachytherapy Isotopes

7.4.5.1 Overview

7.4.5.2 Brachytherapy Isotopes: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

8. APAC Radiopharmaceuticals Market Analysis – By Application

8.1 Overview

8.2 APAC Radiopharmaceuticals Market Revenue Share, by Application (2021 and 2028)

8.3 Oncology

8.3.1 Overview

8.3.2 Oncology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

8.4 Cardiology

8.4.1 Overview

8.4.2 Cardiology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

8.5 Neurology

8.5.1 Overview

8.5.2 Neurology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

8.6 Others

8.6.1 Overview

8.6.2 Others: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

9. APAC Radiopharmaceuticals Market Analysis – By End User

9.1 Overview

9.2 APAC Radiopharmaceuticals Market Share, by End User, 2021 and 2028, (%)

9.3 Hospitals

9.3.1 Overview

9.3.2 Hospitals: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

9.4 Imaging Centres

9.4.1 Overview

9.4.2 Imaging Centres: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

9.5 Academic and Research Centers

9.5.1 Overview

9.5.2 Academic and Research Centers: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

9.6 Others

9.6.1 Overview

9.6.2 Others: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

10. APAC Radiopharmaceuticals Market – Country Analysis

10.1 APAC: Radiopharmaceuticals Market

10.1.1 Overview

10.1.2 APAC: Radiopharmaceuticals Market, by Country, 2021 & 2028 (%)

10.1.2.1 China: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

10.1.2.1.1 China: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

10.1.2.1.2 China: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)

10.1.2.1.2.1 China: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)

10.1.2.1.2.2 China: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)

10.1.2.1.3 China: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)

10.1.2.1.4 China: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)

10.1.2.2 Japan: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

10.1.2.2.1 Japan: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

10.1.2.2.2 Japan: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)

10.1.2.2.2.1 Japan: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)

10.1.2.2.2.2 Japan: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)

10.1.2.2.3 Japan: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)

10.1.2.2.4 Japan: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)

10.1.2.3 India: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

10.1.2.3.1 India: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

10.1.2.3.2 India: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)

10.1.2.3.2.1 India: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)

10.1.2.3.2.2 India: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)

10.1.2.3.3 India: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)

10.1.2.3.4 India: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)

10.1.2.4 Australia: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

10.1.2.4.1 Australia: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

10.1.2.4.2 Australia: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)

10.1.2.4.2.1 Australia: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)

10.1.2.4.2.2 Australia: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)

10.1.2.4.3 Australia: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)

10.1.2.4.4 Australia: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)

10.1.2.5 South Korea: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

10.1.2.5.1 South Korea: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

10.1.2.5.2 South Korea: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)

10.1.2.5.2.1 South Korea: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)

10.1.2.5.2.2 South Korea: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)

10.1.2.5.3 South Korea: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)

10.1.2.5.4 South Korea: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)

10.1.2.6 Rest of APAC: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

10.1.2.6.1 Rest of APAC: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

10.1.2.6.2 Rest of APAC: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)

10.1.2.6.2.1 Rest of APAC: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)

10.1.2.6.2.2 Rest of APAC: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)

10.1.2.6.3 Rest of APAC: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)

10.1.2.6.4 Rest of APAC: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)

11. Impact Of COVID-19 Pandemic on APAC Radiopharmaceuticals Market

11.1 APAC: Impact Assessment of COVID-19 Pandemic

12. Industry Landscape

12.1 Overview

12.2 Inorganic Growth Strategies

12.2.1 Overview

12.3 Organic Growth Strategies

12.3.1 Overview

13. Company Profiles

13.1 Cardinal Health Inc

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 Curium

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 GENERAL ELECTRIC

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

13.3.5 SWOT Analysis

13.3.6 Key Developments

13.4 Lantheus Medical Imaging, Inc.

13.4.1 Key Facts

13.4.2 Business Description

13.4.3 Products and Services

13.4.4 Financial Overview

13.4.5 SWOT Analysis

13.4.6 Key Developments

13.5 Bayer AG

13.5.1 Key Facts

13.5.2 Business Description

13.5.3 Products and Services

13.5.4 Financial Overview

13.5.5 SWOT Analysis

13.5.6 Key Developments

13.6 Bracco Imaging S.p.A

13.6.1 Key Facts

13.6.2 Business Description

13.6.3 Products and Services

13.6.4 Financial Overview

13.6.5 SWOT Analysis

13.6.6 Key Developments

13.7 ECZACIBA?I MONROL NUCLEAR PRODUCTS CO.

13.7.1 Key Facts

13.7.2 Business Description

13.7.3 Products and Services

13.7.4 Financial Overview

13.7.5 SWOT Analysis

13.7.6 Key Developments

13.8 Nordion

13.8.1 Key Facts

13.8.2 Business Description

13.8.3 Products and Services

13.8.4 Financial Overview

13.8.5 SWOT Analysis

13.8.6 Key Developments

13.9 NTP RADIOISOTOPES

13.9.1 Key Facts

13.9.2 Business Description

13.9.3 Products and Services

13.9.4 Financial Overview

13.9.5 SWOT Analysis

13.9.6 Key Developments

13.10 Advanced Accelerator Applications

13.10.1 Key Facts

13.10.2 Business Description

13.10.3 Products and Services

13.10.4 Financial Overview

13.10.5 SWOT Analysis

13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners

14.2 Glossary of Terms

LIST OF TABLES

Table 1. APAC Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

Table 2. China: Radiopharmaceuticals Market, By Type – Revenue and Forecast to 2028 (USD Million)

Table 3. China Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)

Table 4. China Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)

Table 5. China: Radiopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (USD Million)

Table 6. China: Radiopharmaceuticals Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 7. Japan: Radiopharmaceuticals Market, By Type– Revenue and Forecast to 2028 (USD Million)

Table 8. Japan Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)

Table 9. Japan Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)

Table 10. Japan: Radiopharmaceuticals Market, by Application– Revenue and Forecast to 2028 (USD Million)

Table 11. Japan: Radiopharmaceuticals Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 12. India: Radiopharmaceuticals Market, By Type – Revenue and Forecast to 2028 (USD Million)

Table 13. India Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)

Table 14. India Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)

Table 15. India: Radiopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (USD Million)

Table 16. India: Radiopharmaceuticals Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 17. Australia: Radiopharmaceuticals Market, By Type – Revenue and Forecast to 2028 (USD Million)

Table 18. Australia Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)

Table 19. Australia Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)

Table 20. Australia: Radiopharmaceuticals Market, by Application– Revenue and Forecast to 2028 (USD Million)

Table 21. Australia: Radiopharmaceuticals Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 22. South Korea: Radiopharmaceuticals Market, By Type – Revenue and Forecast to 2028 (USD Million)

Table 23. South Korea Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)

Table 24. South Korea Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)

Table 25. South Korea: Radiopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (USD Million)

Table 26. South Korea: Radiopharmaceuticals Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 27. Rest of APAC: Radiopharmaceuticals Market, By Type – Revenue and Forecast to 2028 (USD Million)

Table 28. Rest of APAC Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)

Table 29. Rest of APAC Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)

Table 30. Rest of APAC: Radiopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (USD Million)

Table 31. Rest of APAC: Radiopharmaceuticals Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 32. Recent Inorganic Growth Strategies

Table 33. Recent Organic Growth Strategies

Table 34. Glossary of Terms

LIST OF FIGURES

Figure 1. APAC Radiopharmaceuticals Market Segmentation

Figure 2. APAC Radiopharmaceuticals Market Segmentation, By Country

Figure 3. APAC Radiopharmaceuticals Market Overview

Figure 4. Diagnostic Nuclear Medicine Segment Held the Largest Share of the Market in 2021

Figure 5. India to Show Significant Growth During Forecast Period

Figure 6. APAC PEST Analysis

Figure 7. APAC Radiopharmaceuticals Market Impact Analysis of Drivers and Restraints

Figure 8. APAC Radiopharmaceuticals Market– Revenue Forecast and Analysis

Figure 9. APAC Radiopharmaceuticals Market Revenue Share, by Type (2021 and 2028)

Figure 10. APAC Diagnostic Nuclear Medicine: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 11. APAC SPECT: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 12. APAC PET: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 13. APAC Therapeutic Nuclear Medicine: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 14. APAC Alpha Emitters: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 15. APAC Beta Emitters: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 16. APAC Brachytherapy Isotopes: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 17. APAC Radiopharmaceuticals Market Revenue Share, by Application (2021 and 2028)

Figure 18. APAC Oncology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 19. APAC Cardiology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 20. APAC Neurology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 21. APAC Others: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 22. APAC Radiopharmaceuticals Market Share, by End User, 2021 and 2028 (%)

Figure 23. APAC Hospitals: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 24. APAC Imaging Centres: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 25. APAC Academic and Research Centers: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 26. APAC Others: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 27. APAC: Radiopharmaceuticals Market, by Key Country – Revenue (2021) (USD Million)

Figure 28. APAC: Radiopharmaceuticals Market, by Country, 2021 & 2028 (%)

Figure 29. China: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

Figure 30. Japan: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

Figure 31. India: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

Figure 32. Australia: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

Figure 33. South Korea: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

Figure 34. Rest of APAC: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

Figure 35. Impact of COVID-19 Pandemic in APAC Country Markets

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the APAC radiopharmaceuticals market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the APAC radiopharmaceuticals market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth APAC market trends and outlook coupled with the factors driving the radiopharmaceuticals market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement
Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports

Report Name	Published Date
Asia Pacific Wind Turbine Condition Monitoring Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Component (Hardware, and Software an..	May 2022
Asia Pacific Automotive System Simulation Software Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Transmission, Engine, Elec..	May 2022
Asia Pacific Ground Engaging Tools Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Application (Excavators, Loaders, Bulldozers, an..	May 2022

Purchase Options

Single User License

$3000

$1800

Site License

$4000

$2400

Enterprise License

$5000

$3000

GET FREE SAMPLE PDF

Inquire before Buying Inquire for Discount

Subscription Member Price: FREE

Get Subscription

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

Request for Free Sample